ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

23andMe Allies With Genentech

by Marc S. Reisch
January 12, 2015 | APPEARED IN VOLUME 93, ISSUE 2

Genentech has reached an agreement with 23andMe to generate whole-genome sequencing data from 3,000 volunteers with Parkinson’s disease. The two hope to discover new therapeutic targets for treating the nervous system disorder. 23andMe says it will also be able to share the genetic information generated through the project with other researchers. A year ago, FDA ordered 23andMe to stop selling its direct-to-consumer genome test kits without the agency’s approval.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment